Literature DB >> 30430198

Mitochondrial functions and melatonin: a tour of the reproductive cancers.

Luiz Gustavo de Almeida Chuffa1, Fábio Rodrigues Ferreira Seiva2, Maira Smaniotto Cucielo3, Henrique Spaulonci Silveira3, Russel J Reiter4, Luiz Antonio Lupi3.   

Abstract

Cancers of the reproductive organs have a strong association with mitochondrial defects, and a deeper understanding of the role of this organelle in preneoplastic-neoplastic changes is important to determine the appropriate therapeutic intervention. Mitochondria are involved in events during cancer development, including metabolic and oxidative status, acquisition of metastatic potential, resistance to chemotherapy, apoptosis, and others. Because of their origin from melatonin-producing bacteria, mitochondria are speculated to produce melatonin and its derivatives at high levels; in addition, exogenously administered melatonin accumulates in the mitochondria against a concentration gradient. Melatonin is transported into tumor cell by GLUT/SLC2A and/or by the PEPT1/2 transporters, and plays beneficial roles in mitochondrial homeostasis, such as influencing oxidative phosphorylation and electron flux, ATP synthesis, bioenergetics, calcium influx, and mitochondrial permeability transition pore. Moreover, melatonin promotes mitochondrial homeostasis by regulating nuclear DNA and mtDNA transcriptional activities. This review focuses on the main functions of melatonin on mitochondrial processes, and reviews from a mechanistic standpoint, how mitochondrial crosstalk evolved in ovarian, endometrial, cervical, breast, and prostate cancers relative to melatonin's known actions. We put emphasis on signaling pathways whereby melatonin interferes within cancer-cell mitochondria after its administration. Depending on subtype and intratumor metabolic heterogeneity, melatonin seems to be helpful in promoting apoptosis, anti-proliferation, pro-oxidation, metabolic shifting, inhibiting neovasculogenesis and controlling inflammation, and restoration of chemosensitivity. This results in attenuation of development, progression, and metastatic potential of reproductive cancers, in addition to lowering the risk of recurrence and improving the life quality of patients.

Entities:  

Keywords:  Breast cancer; Cervical cancer; Endometrial cancer; Melatonin; Mitochondrial function; Ovarian cancer; Prostate cancer

Mesh:

Substances:

Year:  2018        PMID: 30430198     DOI: 10.1007/s00018-018-2963-0

Source DB:  PubMed          Journal:  Cell Mol Life Sci        ISSN: 1420-682X            Impact factor:   9.261


  16 in total

1.  Molecular and Clinical Relevance of ZBTB38 Expression Levels in Prostate Cancer.

Authors:  Maud de Dieuleveult; Claire Marchal; Anne Jouinot; Anne Letessier; Benoit Miotto
Journal:  Cancers (Basel)       Date:  2020-04-29       Impact factor: 6.639

2.  MIEF2 over-expression promotes tumor growth and metastasis through reprogramming of glucose metabolism in ovarian cancer.

Authors:  Shuhua Zhao; Xiaohong Zhang; Yuan Shi; Lu Cheng; Tingting Song; Bing Wu; Jia Li; Hong Yang
Journal:  J Exp Clin Cancer Res       Date:  2020-12-14

Review 3.  Melatonin and Cancer: A Polyhedral Network Where the Source Matters.

Authors:  Maria-Angeles Bonmati-Carrion; Antonia Tomas-Loba
Journal:  Antioxidants (Basel)       Date:  2021-02-01

Review 4.  Exosomes and Melatonin: Where Their Destinies Intersect.

Authors:  Adriana Alonso Novais; Luiz Gustavo de Almeida Chuffa; Débora Aparecida Pires de Campos Zuccari; Russel J Reiter
Journal:  Front Immunol       Date:  2021-06-11       Impact factor: 7.561

Review 5.  Melatonin-Loaded Nanocarriers: New Horizons for Therapeutic Applications.

Authors:  Luiz Gustavo de Almeida Chuffa; Fábio Rodrigues Ferreira Seiva; Adriana Alonso Novais; Vinícius Augusto Simão; Virna Margarita Martín Giménez; Walter Manucha; Debora Aparecida Pires de Campos Zuccari; Russel J Reiter
Journal:  Molecules       Date:  2021-06-10       Impact factor: 4.411

Review 6.  Melatonin Promotes Uterine and Placental Health: Potential Molecular Mechanisms.

Authors:  Luiz Gustavo de Almeida Chuffa; Luiz Antonio Lupi; Maira Smaniotto Cucielo; Henrique Spaulonci Silveira; Russel J Reiter; Fábio Rodrigues Ferreira Seiva
Journal:  Int J Mol Sci       Date:  2019-12-31       Impact factor: 5.923

Review 7.  The inhibitory effect of melatonin on human prostate cancer.

Authors:  Dexin Shen; Lingao Ju; Fenfang Zhou; Mengxue Yu; Haoli Ma; Yi Zhang; Tongzu Liu; Yu Xiao; Xinghuan Wang; Kaiyu Qian
Journal:  Cell Commun Signal       Date:  2021-03-15       Impact factor: 5.712

Review 8.  Involvement of NRF2 in Breast Cancer and Possible Therapeutical Role of Polyphenols and Melatonin.

Authors:  Alev Tascioglu Aliyev; Emiliano Panieri; Višnja Stepanić; Hande Gurer-Orhan; Luciano Saso
Journal:  Molecules       Date:  2021-03-25       Impact factor: 4.411

9.  Molecular mechanism of inhibitory effects of melatonin on prostate cancer cell proliferation, migration and invasion.

Authors:  Altannavch Nyamsambuu; Md Asaduzzaman Khan; Xi Zhou; Han-Chun Chen
Journal:  PLoS One       Date:  2022-01-21       Impact factor: 3.240

Review 10.  Targeting Mitochondrial OXPHOS and Their Regulatory Signals in Prostate Cancers.

Authors:  Chia-Lin Chen; Ching-Yu Lin; Hsing-Jien Kung
Journal:  Int J Mol Sci       Date:  2021-12-14       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.